In the end it's a replication problem: What measuring telomere length can tell us about idiopathic pulmonary fibrosis

Respirology

Volumn 20, Issue 6, 2015, Pages 855-856

  Chambers, Daniel C ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

idiopathic pulmonary fibrosis; interstitial lung disease; prognosis; stem cell; telomere

Indexed keywords

DNA; GENOMIC DNA; NINTEDANIB;

CELL DIVISION; CHROMATID; DNA REPLICATION; EDITORIAL; ENVIRONMENTAL EXPOSURE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MESENCHYMAL STROMA CELL; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; TELOMERE; TELOMERE SHORTENING; IDIOPATHIC PULMONARY FIBROSIS; PHYSIOLOGY; TELOMERE HOMEOSTASIS;

HUMANS; IDIOPATHIC PULMONARY FIBROSIS; TELOMERE HOMEOSTASIS;

EID: 84937023364     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12580     Document Type: Editorial

References (13)

1. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-2092.
2. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-2082.
3. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, Markin C, Lawson WE, Xie M, Vulto I, Phillips JA 3rd, et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2007; 356: 1317-1326.
4. Chambers DC, Clarke BE, McGaughran J, Garcia CK,. Lung fibrosis, premature graying, and macrocytosis. Am. J. Respir. Crit. Care Med. 2012; 186: e8-9.
5. Dai J, Cai H, Li H, Zhuang Y, Min H, Wen Y, Yang J, Gao Q, Shi Y, Yi L,. Association between telomere length and survival in patients with idiopathic pulmonary fibrosis. Respirology 2015; 20: doi: 10.1111/resp.12566.
6. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, Cogan JD, Vulto I, Xie M, Qi X, Tuder RM, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. U.S.A. 2008; 105: 13051-13056.
7. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir. Med. 2014; 2: 557-565.
8. Snetselaar R, van Moorsel CH, Kazemier KM, van der Vis JJ, Zanen P, van Oosterhout MF, Grutters JC,. Telomere length in interstitial lung diseases. Chest 2015; doi: 10.1378/chest.14-3078.
9. King TE Jr, Albera C, Bradford WZ, Costabel U, du Bois RM, Leff JA, Nathan SD, Sahn SA, Valeyre D, Noble PW,. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials. Am. J. Respir. Crit. Care Med. 2014; 189: 825-831.
10. Spagnolo P, Grunewald J, du Bois RM,. Genetic determinants of pulmonary fibrosis: evolving concepts. Lancet Respir. Med. 2014; 2: 416-428.
11. Alder JK, Barkauskas CE, Limjunyawong N, Stanley SE, Kembou F, Tuder RM, Hogan BL, Mitzner W, Armanios M,. Telomere dysfunction causes alveolar stem cell failure. Proc. Natl. Acad. Sci. U.S.A. 2015; 112: 5099-5104.
12. Jun D, Garat C, West J, Thorn N, Chow K, Cleaver T, Sullivan T, Torchia EC, Childs C, Shade T, et al. The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation. Stem Cells 2011; 29: 725-735.
13. Chambers DC, Enever D, Ilic N, Sparks L, Whitelaw K, Ayres J, Yerkovich ST, Khalil D, Atkinson KM, Hopkins PM,. A phase 1b study of placenta-derived mesenchymal stromal cells in patients with idiopathic pulmonary fibrosis. Respirology 2014; 19: 1013-1018.